All News

ACR, guidance, guidelines

ACR Newly Revised COVID-19 Vaccine Clinical Guidance for RMD Patients

d ACR

The ACR has updated its clinical guidance for the use of COVID-19 vaccination in patients with musculoskeletal disorders (MSK). 

Read Article
RheumNow Podcast square

The Last Word on JAK Inhibitor Safety & 1133 Study (1.28.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  This week a trifecta of Gout reports and the last word on the ORAL Surveillance study...

Read Article
risk2h.jpg

Risk vs. Benefit Lessons from the ORAL Surveillance Study

d Jack Cush, MD

In an editorial in the current edition of the NEJM, Dr. Jasvinder Singh comments on the Oral Surveillance trial (Ytterberg et al.), a 4-year randomized, open-label, noninferiority, postauthorization, safety end-point trial, in high risk active rheumatoid arthritis patients over age 50 years.

Read Article
virus,COVID,Vaccine, booster

MMWR: Booster Vaccine Efficacy in Immunosuppressed Patients

d CDC/MMWR

For adults aged ≥18 years who received 2 doses of an mRNA COVID-19 vaccine, a third dose increased vaccine effectiveness (prevention of hospitalization) among adults without (82% to 97%) and with immunocompromising conditions (69% to 88%), with near similar efficacy.

Read Article
phys.therapy.knee2_.jpg

Physical Therapy is More Cost-Effective than Intraarticular Steroids in Knee OA

d Jack Cush, MD

A randomized trial compared the incremental cost-effectiveness of physical therapy and intra-articular glucocorticoid (IA GC) injection as initial treatment for knee osteoarthritis showed that physical therapy gained more quality-adjusted life-years compared with those receiving glucocortico

Read Article
renal.stone_.LBP_.jpg

Allopurinol Safety in CKD Patients

d Jack Cush, MD

A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality.

Read Article
We are excited to announce that Dr. Ernest Choy will be joining us at RheumNow Live, leading a presentation on Precision Medicine in Rheumatoid Arthritis. Join the discussion on March 19-20. Invigorate, Instigate and Debate Rheumatology at #RNL2022 https://t.co/4uXQfRvRgc https://t.co/7KcPXadGcY

Links:

Dr. John Cush RheumNow ( View Tweet)
Following a mild bout of COVID-19, Dr. Kathryn Dao, shares insights on the best way to handle mild cases whether it is yourself or a friend/family member who has COVID19. https://t.co/mevbQVNjPp ( @KDAO2011) https://t.co/CSzB9ChH3r

Links:

Dr. John Cush RheumNow ( View Tweet)
Article in JAMA estimates that there are 110,000 LESS deaths per year when US adults aged 40-85 years or older had a modest increase in their modest increases in moderate-to-vigorous physical activity intensity per day (ie, 10 minutes per day) https://t.co/n1ictmjnqi

Links:

Dr. John Cush RheumNow ( View Tweet)

2021 approved Efgartigimod (Vyvgart) for myasthenia gravis: (binds neonatal Fc receptor, stops Ig recirculation): pts w/ AChR Abs respond best (68% vs 30%). Common AEs include URI, UTI, HA; other AE: eyelid swelling, rash, and SOB. https://t.co/wQKZuAlXoR

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: MMWR reports >40,000 pregnant women who received COVID-19 vaccination during pregnancy- VAX not associated with preterm birth or small-for-gestational-age at birth overall compared with unvaccinated pregnant women. https://t.co/GtRMsNrFnn

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: How Preventable Is Rheumatoid Arthritis? https://t.co/epc6BvYKzq https://t.co/2hKIuE66zT

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: NEJM clinical case -42 yoM w/ red, painful eyes, facial-nerve palsy OS, a large oral ulcer, and petechiae. +ANCA, +PR3. Skin biopsy revealed leukocytoclastic vasculitis with perivascular eosinophils. Dx eosinophilic granulomatosis with polyangiitis https://t.co/zXTQYfPa1t

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Physical Therapy is More Cost-Effective than Intraarticular Steroids in Knee OA https://t.co/My5xa8vEaP https://t.co/lGL57nwJiZ

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: FDA Approves Skyrizi for Active Psoriatic Arthritis https://t.co/0HpoZYHK2V https://t.co/pvIC6ECqjF

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: FREED study (asympt hyperuricemic without gout) showed febuxostat x 24 mos dint alter carotid atherosclerosis, but at 3 years, (Substudy of 1004 pts), showed FEB signif lowered risk of CVA, CV, renal renal events and death (vs PBO) https://t.co/x2pYrOBZVG

Links:

Dr. John Cush RheumNow ( View Tweet)

Dr. Ernest Choy will be part of the Rheumatoid Faculty panel Q&A at RheumNow Live this March. Grab the mic & ask a question! Register Today! https://t.co/aJYMyKMGMn #RNL2022 https://t.co/oH4oG797XA

Links:

Dr. John Cush RheumNow ( View Tweet)
Join Dr. Cush at RheumNow Live this March as he presents and discusses Treatment Choices in Refractory RA. https://t.co/11XNOQOwm0 https://t.co/Ar4QeoRRTz

Links:

Dr. John Cush RheumNow ( View Tweet)
From 1969 hospitalized COVID Spanish pts (46% F, age 61), 31 pts w/ preexisting RMD -- they did not have more long-term post-COVID sxs (OR 1.46; 0.89–2.4), functional limitation (OR 1.058), anxiety, depression or MSK pain vs non-RMD https://t.co/IYJz5zFoLe

Links:

Dr. John Cush RheumNow ( View Tweet)

819 rheumatic disease pts surved about Telemedicine (TM), available to most (75%). Satisfaction was 7.3/10 w/ 26% very satisfied. Pts preferred TM for routine visits (73%), test results (65%), med changes (41%); but less so for new Injx meds(19%) https://t.co/W8newba0FV

Links:

Dr. John Cush RheumNow ( View Tweet)

×